News

Commentary: Digital health companies should stay away from FDA in 2021 | News from healthcareitnews.com

By December 23, 2020No Comments


As the agency’s workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green’s Bradley Merrill Thompson.
News from healthcareitnews.com

Leave a Reply